Companion and Complementary Diagnostics

Companion and Complementary Diagnostics
Author: Jan Trøst Jørgensen
Publsiher: Academic Press
Total Pages: 508
Release: 2019-05-08
ISBN 10: 0128135409
ISBN 13: 9780128135402
Language: EN, FR, DE, ES & NL

Companion and Complementary Diagnostics Book Review:

Companion and Complementary Diagnostics: From Biomarker Discovery to Clinical Implementation provides readers with in-depth insights into the individual steps in the development of companion diagnostic assays, from the early biomarker discovery phase straight through to final regulatory approval. Further, the clinical implementation of companion diagnostic testing in the clinic is also discussed. As the development of predictive or selective biomarker assays linked to specific drugs is substantially increasing, this book offers comprehensive information on this quickly-evolving area of biomedicine. It is an essential resource for those in academic institutions, hospitals and pharma, and biotech and diagnostic commercial companies. Covers all aspects, from biomarker discovery, to development and regulatory approval Explains the "how to" aspects of companion diagnostics Incorporates information on the entire process, allowing for easier and deeper understanding of the topic

Companion Diagnostics CDx in Precision Medicine

Companion Diagnostics  CDx  in Precision Medicine
Author: Il-Jin Kim
Publsiher: CRC Press
Total Pages: 256
Release: 2019-03-06
ISBN 10: 1000007219
ISBN 13: 9781000007213
Language: EN, FR, DE, ES & NL

Companion Diagnostics CDx in Precision Medicine Book Review:

There is a new trend in anti-cancer therapeutics development: a targeted therapy and precision medicine that targets a subgroup of patients with specific biomarkers. An in vitro diagnostic (IVD) assay is required to identify a subgroup of cancer patients who would benefit from the targeted therapy, or not likely benefit, or have a high risk of side effects from the specific drug treatment. This IVD or medical device is called a companion diagnostic (CDx) assay. It is key to have a robust CDx assay or device for the success of targeted therapy and precision medicine. This book covers the technical, historical, clinical, and regulatory aspects of CDx in precision medicine. Clearly, more and more newly developed oncology drugs will require accompanying CDx assays, and this book, with chapters contributed by renowned oncologists, provides a comprehensive foundation for the knowledge and application of CDx for precision medicine.

Drug Diagnostics Co Development in Oncology

Drug Diagnostics Co Development in Oncology
Author: Jan Trøst Jørgensen
Publsiher: Frontiers E-books
Total Pages: 135
Release: 2014-11-07
ISBN 10: 2889193322
ISBN 13: 9782889193325
Language: EN, FR, DE, ES & NL

Drug Diagnostics Co Development in Oncology Book Review:

The idea of combining drugs and diagnostics in oncology is not new. When the selective estrogen receptor modulator tamoxifen was developed in the 1970’s for the treatment of breast cancer a positive correlation between receptor status and treatment outcome was found. As a result of this research, it was suggested to use the estrogen-receptor assay as a diagnostic test for selection of patients for tamoxifen treatment. Despite this suggestion was put forward nearly 40 years ago the adaptation of the drug-diagnostic co-development model has been relatively slow and it is only within the last decade that it has gained more widespread acceptance. The parallel development of the monoclonal antibody trastuzumab (Herceptin®, Roche/Genentech) and the immunohistochemistry assay for HER2 protein overexpression (HercepTest™, Dako) seems to have served as an inspiration to a number of stakeholders such as pharma and diagnostic companies, regulatory agencies, and academia. In recent years we have seen an increasing number of oncology drug development projects that have taken advantage of the drug-diagnostic co-development model, as outline below. Most of the new targeted anti-cancer drugs that have been introduced in recent years, such as BRAF-, ALK-, EGFR- and HER2-inhibitors, are more or less all a product of the drugdiagnostic co-development model. These drugs have shown remarkable high response rates in selected groups of patients within cancer diseases with great unmet medical needs. This Research Topic on Drug-Diagnostic Co-Development in Oncology aims to provide you with an insight into some of the diverse activities that constitute this new research area.

Handbook of Biomarkers and Precision Medicine

Handbook of Biomarkers and Precision Medicine
Author: Claudio Carini,Mark Fidock,Alain van Gool
Publsiher: CRC Press
Total Pages: 631
Release: 2019-04-16
ISBN 10: 0429574622
ISBN 13: 9780429574627
Language: EN, FR, DE, ES & NL

Handbook of Biomarkers and Precision Medicine Book Review:

"The field of Biomarkers and Precision Medicine in drug development is rapidly evolving and this book presents a snapshot of exciting new approaches. By presenting a wide range of biomarker applications, discussed by knowledgeable and experienced scientists, readers will develop an appreciation of the scope and breadth of biomarker knowledge and find examples that will help them in their own work." -Maria Freire, Foundation for the National Institutes of Health Handbook of Biomarkers and Precision Medicine provides comprehensive insights into biomarker discovery and development which has driven the new era of Precision Medicine. A wide variety of renowned experts from government, academia, teaching hospitals, biotechnology and pharmaceutical companies share best practices, examples and exciting new developments. The handbook aims to provide in-depth knowledge to research scientists, students and decision makers engaged in Biomarker and Precision Medicine-centric drug development. Features: Detailed insights into biomarker discovery, validation and diagnostic development with implementation strategies Lessons-learned from successful Precision Medicine case studies A variety of exciting and emerging biomarker technologies The next frontiers and future challenges of biomarkers in Precision Medicine Claudio Carini, Mark Fidock and Alain van Gool are internationally recognized as scientific leaders in Biomarkers and Precision Medicine. They have worked for decades in academia and pharmaceutical industry in EU, USA and Asia. Currently, Dr. Carini is Honorary Faculty at Kings’s College School of Medicine, London, UK. Dr. Fidock is Vice President of Precision Medicine Laboratories at AstraZeneca, Cambridge, UK. Prof.dr. van Gool is Head Translational Metabolic Laboratory at Radboud university medical school, Nijmegen, NL.

Precision Medicine and Artificial Intelligence

Precision Medicine and Artificial Intelligence
Author: Michael Mahler
Publsiher: Elsevier
Total Pages: 300
Release: 2021-04-15
ISBN 10: 0128202394
ISBN 13: 9780128202395
Language: EN, FR, DE, ES & NL

Precision Medicine and Artificial Intelligence Book Review:

Precision Medicine and Artificial Intelligence: The Perfect Fit for Autoimmunity covers background on AI, its link to PM, and examples of AI in healthcare, especially autoimmunity. The book highlights future perspectives and potential directions as artificial intelligence (AI) has gained significant attention in the past decade. Autoimmune diseases are complex and heterogeneous conditions, but exciting new developments and implementation tactics surrounding automated systems has enabled the generation of large amounts of data, making autoimmunity an ideal target for AI in the field of Precision Medicine (PM). More and more diagnostic products utilize AI, which is also starting to be supported by regulatory agencies such as the Food and Drug Administration (FDA). Knowledge generation by leveraging large data sets including demographic, environmental, clinical and biomarker data has the potential to not only impact the diagnosis of patients, but also disease prediction, prognosis and treatment options. Allows the readers to get a good overview of the field of Precision Medicine for autoimmune diseases and Artificial Intelligence Provides background, milestone and examples of precision medicine for autoimmune disease and artificial intelligence Proves the paradigm shift towards precision medicine driven by value-based systems Discusses future applications of precision medicine research using artificial intelligence

An R Companion to Applied Regression

An R Companion to Applied Regression
Author: John Fox,Sanford Weisberg
Publsiher: SAGE Publications
Total Pages: 608
Release: 2018-09-27
ISBN 10: 1544336454
ISBN 13: 9781544336459
Language: EN, FR, DE, ES & NL

An R Companion to Applied Regression Book Review:

An R Companion to Applied Regression is a broad introduction to the R statistical computing environment in the context of applied regression analysis. John Fox and Sanford Weisberg provide a step-by-step guide to using the free statistical software R, an emphasis on integrating statistical computing in R with the practice of data analysis, coverage of generalized linear models, and substantial web-based support materials. The Third Edition has been reorganized and includes a new chapter on mixed-effects models, new and updated data sets, and a de-emphasis on statistical programming, while retaining a general introduction to basic R programming. The authors have substantially updated both the car and effects packages for R for this edition, introducing additional capabilities and making the software more consistent and easier to use. They also advocate an everyday data-analysis workflow that encourages reproducible research. To this end, they provide coverage of RStudio, an interactive development environment for R that allows readers to organize and document their work in a simple and intuitive fashion, and then easily share their results with others. Also included is coverage of R Markdown, showing how to create documents that mix R commands with explanatory text.

Predictive Biomarkers in Oncology

Predictive Biomarkers in Oncology
Author: Sunil Badve,George Louis Kumar
Publsiher: Springer
Total Pages: 642
Release: 2018-12-06
ISBN 10: 3319952285
ISBN 13: 9783319952284
Language: EN, FR, DE, ES & NL

Predictive Biomarkers in Oncology Book Review:

“Precision/personalized or stratified medicine” refers to the tailoring of medical treatment or drug administration to the individual characteristics of each patient treatment. It does not literally mean that a pharmaceutical company makes a drug for an individual patient for consumption and treatment but rather means the ability to stratify (or classify) individuals into sub-populations that differ in their responsiveness to a specific drug. A marker that provides information on the likely response to therapy, i.e., either in terms of tumor shrinkage or survival of the patient is termed “predictive biomarker”. Despite their promise in precision medicine and the explosion of knowledge in this area, there is not a single source on this subject that puts all this evidence together in a concise or richly illustrated and easy to understand manner. This book provides a collection of ingeniously organized, well-illustrated and up-to-date authoritative chapters divided into five sections that are clear and easy to understand. Section one provides an overview of biomarkers, introduces the basic terminologies, definitions, technologies, tools and concepts associated with this subject in the form of illustrations/graphics, photographs and concise texts. Several recent biomarker endeavors that have been initiated and funded by the National Cancer Institute, National Institutes of Health, FDA and other International organizations are presented. Section two involves the signaling pathways controlling cell growth and differentiation altered in cancer. This section analyzes how predictive biomarkers are altered (expressed or amplified) across cancer types. Section three explores how predictive biomarkers play a role in patient stratification and tailored treatment in relationship to specific cancers. In addition, it includes discussion on the various precision medicine initiatives that are going on across the globe (e.g. TARGET, NCI-MATCH, BATTLE, SHIVA, etc.). Section four discusses: (a) how pharmaceutical companies validate predictive biomarker assays and accompanying companion diagnostics either internally or externally with partner companies such as central laboratories or clinical research organizations, and (b) how predictive biomarker tests fall under the oversight of US FDA, Centers for Medicare & Medicaid Services (CMS) and state laws. Section five wraps up novel agents and targets that are being used as targets for cancer therapeutics. The biomarkers associated with these protocols will also be presented. Throughout the book, sidebars, special interest boxes and illustrations are used to explain terms that are either newly introduced, uncommon, or specialized. Predictive Biomarkers in Oncology will serve as a definitive guide for practicing pathologists, oncologists, basic researchers, and personnel in the pharmaceutical or diagnostic industry interested in learning how “predictive biomarkers” are used in precision cancer therapy.

Biomarker Tests for Molecularly Targeted Therapies

Biomarker Tests for Molecularly Targeted Therapies
Author: National Academies of Sciences, Engineering, and Medicine,Institute of Medicine,Board on Health Care Services,Committee on Policy Issues in the Clinical Development and Use of Biomarkers for Molecularly Targeted Therapies
Publsiher: National Academies Press
Total Pages: 293
Release: 2016-07-30
ISBN 10: 0309381347
ISBN 13: 9780309381345
Language: EN, FR, DE, ES & NL

Biomarker Tests for Molecularly Targeted Therapies Book Review:

Every patient is unique, and the evolving field of precision medicine aims to ensure the delivery of the right treatment to the right patient at the right time. In an era of rapid advances in biomedicine and enhanced understanding of the genetic basis of disease, health care providers increasingly have access to advanced technologies that may identify molecular variations specific to an individual patient, which subsequently can be targeted for treatment. Known as biomarker tests for molecularly targeted therapies, these complex tests have the potential to enable the selection of the most beneficial treatment (and also to identify treatments that may be harmful or ineffective) for the molecular underpinnings of an individual patient's disease. Such tests are key to unlocking the promise of precision medicine. Biomarker tests for molecularly targeted therapies represent a crucial area of focus for developing methods that could later be applicable to other areas of precision medicine. The appropriate regulatory oversight of these tests is required to ensure that they are accurate, reliable, properly validated, and appropriately implemented in clinical practice. Moreover, common evidentiary standards for assessing the beneficial impact of biomarker-guided therapy selection on patient outcomes, as well as the effective collection and sharing of information related to those outcomes, are urgently needed to better inform clinical decision making. Biomarker Tests of Molecularly Targeted Therapies examines opportunities for and challenges to the use of biomarker tests to select optimal therapy and offers recommendations to accelerate progress in this field. This report explores regulatory issues, reimbursement issues, and clinical practice issues related to the clinical development and use of biomarker tests for targeting therapies to patients. Properly validated, appropriately implemented biomarker tests hold the potential to enhance patient care and improve outcomes, and therefore addressing the challenges facing such tests is critical.

Handbook of Therapeutic Biomarkers in Cancer

Handbook of Therapeutic Biomarkers in Cancer
Author: Sherry X. Yang,Janet E. Dancey
Publsiher: CRC Press
Total Pages: 518
Release: 2013-06-21
ISBN 10: 9814364665
ISBN 13: 9789814364669
Language: EN, FR, DE, ES & NL

Handbook of Therapeutic Biomarkers in Cancer Book Review:

In this volume, a team of internationally recognized experts provide an in-depth description of therapeutic biomarkers across a broad area of cancer research and oncology. With a wealth of information to specific therapies, each chapter focuses on a class of targeted chemotherapy agents. The book describes established and evolving diagnostic tests for therapeutic biomarkers that predict benefit, response, resistance, or drug side effects from specific therapeutic interventions. This volume is an essential handbook for health professionals and scientists researching current applicable biomarkers in oncology.

Diagnostics at a Crossroads Navigating IVD Regulation in a Changing Environment

Diagnostics at a Crossroads  Navigating IVD Regulation in a Changing Environment
Author: Jeffrey Gibbs,Allyson Mullen
Publsiher: Unknown
Total Pages: 135
Release: 2020-12-20
ISBN 10: 9781935065890
ISBN 13: 1935065890
Language: EN, FR, DE, ES & NL

Diagnostics at a Crossroads Navigating IVD Regulation in a Changing Environment Book Review:

Innovations for Next Generation Antibody Drug Conjugates

Innovations for Next Generation Antibody Drug Conjugates
Author: Marc Damelin
Publsiher: Springer
Total Pages: 357
Release: 2018-05-29
ISBN 10: 3319781545
ISBN 13: 9783319781549
Language: EN, FR, DE, ES & NL

Innovations for Next Generation Antibody Drug Conjugates Book Review:

Antibody-drug conjugates (ADCs) stand at the verge of a transformation. Scores of clinical programs have yielded only a few regulatory approvals, but a wave of technological innovation now empowers us to overcome past technical challenges. This volume focuses on the next generation of ADCs and the innovations that will enable them. The book inspires the future by integrating the field’s history with novel strategies and cutting-edge technologies. While the book primarily addresses ADCs for solid tumors, the last chapter explores the emerging interest in using ADCs to treat other diseases. The therapeutic rationale of ADCs is strong: to direct small molecules to the desired site of action (and away from normal tissues) by conjugation to antibodies or other targeting moieties. However, the combination of small and large molecules imposes deep complexity to lead optimization, pharmacokinetics, toxicology, analytics and manufacturing. The field has made significant advances in all of these areas by improving target selection, ADC design, manufacturing methods and clinical strategies. These innovations will inspire and educate scientists who are designing next-generation ADCs with the potential to transform the lives of patients.

Biomarkers in Drug Development

Biomarkers in Drug Development
Author: Michael R. Bleavins,Claudio Carini,Mallé Jurima-Romet,Ramin Rahbari
Publsiher: John Wiley & Sons
Total Pages: 663
Release: 2011-09-20
ISBN 10: 1118210425
ISBN 13: 9781118210420
Language: EN, FR, DE, ES & NL

Biomarkers in Drug Development Book Review:

Discover how biomarkers can boost the success rate of drug development efforts As pharmaceutical companies struggle to improve the success rate and cost-effectiveness of the drug development process, biomarkers have emerged as a valuable tool. This book synthesizes and reviews the latest efforts to identify, develop, and integrate biomarkers as a key strategy in translational medicine and the drug development process. Filled with case studies, the book demonstrates how biomarkers can improve drug development timelines, lower costs, facilitate better compound selection, reduce late-stage attrition, and open the door to personalized medicine. Biomarkers in Drug Development is divided into eight parts: Part One offers an overview of biomarkers and their role in drug development. Part Two highlights important technologies to help researchers identify new biomarkers. Part Three examines the characterization and validation process for both drugs and diagnostics, and provides practical advice on appropriate statistical methods to ensure that biomarkers fulfill their intended purpose. Parts Four through Six examine the application of biomarkers in discovery, preclinical safety assessment, clinical trials, and translational medicine. Part Seven focuses on lessons learned and the practical aspects of implementing biomarkers in drug development programs. Part Eight explores future trends and issues, including data integration, personalized medicine, and ethical concerns. Each of the thirty-eight chapters was contributed by one or more leading experts, including scientists from biotechnology and pharmaceutical firms, academia, and the U.S. Food and Drug Administration. Their contributions offer pharmaceutical and clinical researchers the most up-to-date understanding of the strategies used for and applications of biomarkers in drug development.

The UltraMind Solution

The UltraMind Solution
Author: Mark Hyman
Publsiher: Simon and Schuster
Total Pages: 464
Release: 2008-12-30
ISBN 10: 1416566058
ISBN 13: 9781416566052
Language: EN, FR, DE, ES & NL

The UltraMind Solution Book Review:

From the ten-time New York Times bestselling author of Ultrametabolism, The Blood Sugar Solution, and Eat Fat, Get Thin comes The UltraMind Solution. —Do you find it next to impossible to focus or concentrate? —Have you ever experienced instant clarity after exercise? Alertness after drinking coffee? —Does your brain inexplicably slow down during stress, while multitasking, or when meeting a deadline? —Do you get anxious, worried, or stressed-out frequently? In The UltraMind Solution, Dr. Mark Hyman explains that to fix your broken brain, you must heal your body first. Through his simple six-week plan, Dr. Hyman shows us how to correct imbalances caused by nutritional deficiencies, allergens, infections, toxins, and stress, restoring our health and gaining an UltraMind—one that’s highly focused, able to pay attention at will, has a strong memory, and leaves us feeling calm, confident, in control, and in good spirits.

Molecular Targeted Therapy of Lung Cancer

Molecular Targeted Therapy of Lung Cancer
Author: Yuichi Takiguchi
Publsiher: Springer
Total Pages: 327
Release: 2017-01-24
ISBN 10: 9811020027
ISBN 13: 9789811020025
Language: EN, FR, DE, ES & NL

Molecular Targeted Therapy of Lung Cancer Book Review:

This book discusses the latest molecular targeted therapy of lung cancer including its evaluation and future directions. It clearly illustrates the initial dramatic effectiveness of molecular targeted therapy, recurrence of the disease, overcoming the wide variety of resistance mechanisms using new-generation molecular targeted agents and potential novel approaches. It also outlines the increasing necessity for new diagnostic technology and strategies for managing different adverse effects and novel methods for evaluating effectiveness and safety. Edited and authored by opinion leaders, Molecular Targeted Therapy of Lung Cancer provides a comprehensive overview of the disease and its treatments. It is a valuable resource for graduate students, post-doctoral fellows and faculty staff, as well as researchers involved in clinical and translational research on lung cancer, helping promote new ideas for further advances.

Risk and Reasoning in Clinical Diagnosis

Risk and Reasoning in Clinical Diagnosis
Author: Cym Anthony Ryle
Publsiher: Oxford University Press, USA
Total Pages: 209
Release: 2019-07-12
ISBN 10: 0190944005
ISBN 13: 9780190944001
Language: EN, FR, DE, ES & NL

Risk and Reasoning in Clinical Diagnosis Book Review:

Accurate diagnosis is the foundation of medical practice, but at the start of the diagnostic process, uncertainty is inevitable. The clinician's skills and cognitive attributes determine the quality of the initial differential diagnosis and thus the crucial first phases of investigation and treatment; mistakes are often self-propagating. Diagnostic error is a major cause of avoidable morbidity and mortality, and is the commonest reason for successful litigation. Risk and Reasoning in Clinical Diagnosis is an accessible and readable look at the diagnostic process. Dr. Cym Ryle presents the insights and concepts developed in cognitive psychology which have led to the consensus that in all domains human reasoning is primarily driven by unconscious, intuitive mechanisms; the contribution of structured, analytical thinking is variable and inconsistent. He notes that the risk of error is inseparable from these mechanisms. Dr. Ryle then develops a description of the diagnostic process which encompasses its form, strengths and fallibility, and illustrates this description with examples from his work as a general practitioner. He argues that improving diagnostic accuracy should be a priority, and that there is sufficient evidence to guide changes in medical training, in clinical practice, and in the culture and organisation of our institutions. He identifies specific, practical steps that can be taken by individual clinicians and by clinical teams, suggests priorities for action in our institutions, and considers the obstacles to progress.

The American Psychiatric Association Practice Guidelines for the Psychiatric Evaluation of Adults Third Edition

The American Psychiatric Association Practice Guidelines for the Psychiatric Evaluation of Adults  Third Edition
Author: American Psychiatric Association
Publsiher: American Psychiatric Pub
Total Pages: 172
Release: 2015-07-29
ISBN 10: 0890424659
ISBN 13: 9780890424650
Language: EN, FR, DE, ES & NL

The American Psychiatric Association Practice Guidelines for the Psychiatric Evaluation of Adults Third Edition Book Review:

Since the publication of the Institute of Medicine (IOM) report Clinical Practice Guidelines We Can Trust in 2011, there has been an increasing emphasis on assuring that clinical practice guidelines are trustworthy, developed in a transparent fashion, and based on a systematic review of the available research evidence. To align with the IOM recommendations and to meet the new requirements for inclusion of a guideline in the National Guidelines Clearinghouse of the Agency for Healthcare Research and Quality (AHRQ), American Psychiatric Association (APA) has adopted a new process for practice guideline development. Under this new process APA's practice guidelines also seek to provide better clinical utility and usability. Rather than a broad overview of treatment for a disorder, new practice guidelines focus on a set of discrete clinical questions of relevance to an overarching subject area. A systematic review of evidence is conducted to address these clinical questions and involves a detailed assessment of individual studies. The quality of the overall body of evidence is also rated and is summarized in the practice guideline. With the new process, recommendations are determined by weighing potential benefits and harms of an intervention in a specific clinical context. Clear, concise, and actionable recommendation statements help clinicians to incorporate recommendations into clinical practice, with the goal of improving quality of care. The new practice guideline format is also designed to be more user friendly by dividing information into modules on specific clinical questions. Each module has a consistent organization, which will assist users in finding clinically useful and relevant information quickly and easily. This new edition of the practice guidelines on psychiatric evaluation for adults is the first set of the APA's guidelines developed under the new guideline development process. These guidelines address the following nine topics, in the context of an initial psychiatric evaluation: review of psychiatric symptoms, trauma history, and treatment history; substance use assessment; assessment of suicide risk; assessment for risk of aggressive behaviors; assessment of cultural factors; assessment of medical health; quantitative assessment; involvement of the patient in treatment decision making; and documentation of the psychiatric evaluation. Each guideline recommends or suggests topics to include during an initial psychiatric evaluation. Findings from an expert opinion survey have also been taken into consideration in making recommendations or suggestions. In addition to reviewing the available evidence on psychiatry evaluation, each guideline also provides guidance to clinicians on implementing these recommendations to enhance patient care.

Ten Types of Innovation

Ten Types of Innovation
Author: Larry Keeley,Helen Walters,Ryan Pikkel,Brian Quinn
Publsiher: John Wiley & Sons
Total Pages: 288
Release: 2013-07-15
ISBN 10: 1118571398
ISBN 13: 9781118571392
Language: EN, FR, DE, ES & NL

Ten Types of Innovation Book Review:

Innovation principles to bring about meaningful and sustainablegrowth in your organization Using a list of more than 2,000 successful innovations,including Cirque du Soleil, early IBM mainframes, the Ford Model-T,and many more, the authors applied a proprietary algorithm anddetermined ten meaningful groupings—the Ten Types ofInnovation—that provided insight into innovation. The TenTypes of Innovation explores these insights to diagnosepatterns of innovation within industries, to identify innovationopportunities, and to evaluate how firms are performing againstcompetitors. The framework has proven to be one of the mostenduring and useful ways to start thinking abouttransformation. Details how you can use these innovation principles to bringabout meaningful—and sustainable—growth within yourorganization Author Larry Keeley is a world renowned speaker, innovationconsultant, and president and co-founder of Doblin, the innovationpractice of Monitor Group; BusinessWeek named Keeley one of sevenInnovation Gurus who are changing the field The Ten Types of Innovation concept has influenced thousands ofexecutives and companies around the world since its discovery in1998. The Ten Types of Innovation is the first bookexplaining how to implement it.

Power Transformer Diagnostics Monitoring and Design Features

Power Transformer Diagnostics  Monitoring and Design Features
Author: Issouf Fofana, Ph.D. ing. Chairholder
Publsiher: MDPI
Total Pages: 254
Release: 2019-01-09
ISBN 10: 3038974412
ISBN 13: 9783038974413
Language: EN, FR, DE, ES & NL

Power Transformer Diagnostics Monitoring and Design Features Book Review:

This book is a printed edition of the Special Issue "Power Transformer Diagnostics, Monitoring and Design Features" that was published in Energies

Pocket Atlas of Pulse Diagnosis

Pocket Atlas of Pulse Diagnosis
Author: Cheng-Hong Lin
Publsiher: Thieme Medical Publishers
Total Pages: 254
Release: 2008
ISBN 10: 9783131440518
ISBN 13: 3131440511
Language: EN, FR, DE, ES & NL

Pocket Atlas of Pulse Diagnosis Book Review:

The Pocket Atlas of Pulse Diagnosis unravels the mystery of pulse diagnosis. Detailed explanations of the 28 individual pulses are presented, along with simple diagrams that vividly illustrate how the different pulses should feel like under the fingers at each level of palpation.

Essential Concepts in Molecular Pathology

Essential Concepts in Molecular Pathology
Author: William B. Coleman,Gregory J. Tsongalis
Publsiher: Academic Press
Total Pages: 462
Release: 2010-02-16
ISBN 10: 9780080922188
ISBN 13: 008092218X
Language: EN, FR, DE, ES & NL

Essential Concepts in Molecular Pathology Book Review:

This streamlined "essential" version of the Molecular Pathology (2009) textbook extracts key information, illustrations and photographs from the main textbook in the same number and organization of chapters. It is aimed at teaching students in courses where the full textbook is not needed, but the concepts included are desirable (such as graduate students in allied health programs or undergraduates). It is also aimed at students who are enrolled in courses that primarily use a traditional pathology textbook, but need the complementary concepts of molecular pathology (such as medical students). Further, the textbook will be valuable for pathology residents and other postdoctoral fellows who desire to advance their understanding of molecular mechanisms of disease beyond what they learned in medical/graduate school. Offers an essential introduction to molecular genetics and the "molecular" aspects of human disease Teaches from the perspective of "integrative systems biology," which encompasses the intersection of all molecular aspects of biology, as applied to understanding human disease In-depth presentation of the principles and practice of molecular pathology: molecular pathogenesis, molecular mechanisms of disease, and how the molecular pathogenesis of disease parallels the evolution of the disease using histopathology. "Traditional" pathology section provides state-of-the-art information on the major forms of disease, their pathologies, and the molecular mechanisms that drive these diseases. Explains the practice of "molecular medicine" and the translational aspects of molecular pathology: molecular diagnostics, molecular assessment, and personalized medicine Each chapter ends with Key Summary Points and Suggested Readings